Pediatric Oncology

Top Story

IV pegylated asparaginase shows promise for pediatric ALL

February 12, 2016

IV pegylated asparaginase yielded similar efficacy as intramuscular native Escherichia coli L-asparaginase without increasing toxicity in pediatric patients with newly diagnosed acute lymphoblastic leukemia, according to the results of a phase 3 trial.

Further, IV pegylated asparaginase (PEG-asparaginase) appeared to decrease patient anxiety, which supported its use as a first-line asparaginase preparation in this patient population.

In the Journals

Experts reveal ‘troubling’ industry-employed strategies to delay availability of generic cancer drugs

February 8, 2016
Pharmaceutical companies have employed several strategies — including reverse payment, patent settlements and “product hopping” — to prevent…
FDA News

FDA grants orphan drug designation to tazemetostat for treatment of malignant rhabdoid tumors

February 8, 2016
The FDA granted orphan drug status to tazemetostat for the treatment of malignant rhabdoid tumors, according to a press release from the agent’s manufacturer.The…

Children’s Research Institute at Children’s Mercy appoints chief scientific officer

February 6, 2016
Tom Curran, PhD, FRS, has been hired as chief scientific officer and executive director of Children’s Research Institute at Children’s Mercy Kansas City.The…
In the Journals

IV pegylated asparaginase shows promise for pediatric ALL

February 12, 2016
IV pegylated asparaginase yielded similar efficacy as intramuscular native Escherichia coli L-asparaginase without increasing toxicity in pediatric…
In the Journals

Experts reveal ‘troubling’ industry-employed strategies to delay availability of generic cancer drugs

February 8, 2016
Pharmaceutical companies have employed several strategies — including reverse payment, patent settlements and “product hopping”…
FDA News

FDA grants orphan drug designation to tazemetostat for treatment of malignant rhabdoid tumors

February 8, 2016
The FDA granted orphan drug status to tazemetostat for the treatment of malignant rhabdoid tumors, according to a press release from the…

Children’s Research Institute at Children’s Mercy appoints chief scientific officer

February 6, 2016
Tom Curran, PhD, FRS, has been hired as chief scientific officer and executive director of Children’s Research Institute at Children’s…
In the JournalsPerspective

Adult survivors of pediatric brain tumors face significant long-term cognitive impairment

February 5, 2016
Survivors of pediatric brain tumors appeared at risk for severe cognitive impairment in adulthood, according to findings from a study conducted by…
In the Journals

World Cancer Day: ‘We can’ reduce global cancer burden

February 4, 2016
Today marks the annual observation of World Cancer Day, founded by the Union for International Cancer Control to raise awareness of cancer and…
In the Journals

Gemtuzumab ozogamicin response linked to CD33 expression level in pediatric AML

February 3, 2016
Treatment with gemtuzumab ozogamicin appeared to significantly reduce relapse risk and extend EFS in pediatric patients with acute myeloid leukemia…

Children’s Hospital Los Angeles names director of Center for Personalized Medicine

February 3, 2016
Jaclyn Biegel, PhD, has been named director of the Center for Personalized Medicine at Children’s Hospital Los Angeles.Biegel ― known for her…
In the Journals

Proton beam therapy reduces toxicity in treatment of pediatric medulloblastoma

February 3, 2016
Proton radiotherapy appeared as effective as but less toxic than conventional photon radiotherapy for the treatment of children with medulloblastoma…
In the JournalsPerspective

Panel issues framework for allocation of scarce pediatric oncology drugs

January 29, 2016
Pediatric oncology and bioethics experts have issued a framework for the allocation of scarce drugs to reduce waste and prioritize treatment across…
More Headlines »
morganatic-roan